SANTA BARBARA, Calif., July 26 /PRNewswire-FirstCall/ — Abviva,
Inc. (Pink Sheets: ABVV), a biomedical company engaged in the
development and commercialization of breast cancer-related
applications of Mammastatin, announced that the Canadian Patent
Office issued notice that it will be issuing patent application
Number 2.267.095 within 12 weeks.
The Mammastatin technology continues to increase its protection
as evidenced by the granting of patents around its core technology.
In recent months, the Japanese Patent Office issued two
patents on the Mammastatin technology, and the Canadian patent will
help protect the technology when it begins international
expansion.
“The Company is very pleased with this notice of patent to be
granted and believes that the issuance of the many patents will
allow Abviva to expand internationally in years to come,” said
Barrett Evans, Abviva’s CEO.
About Abviva
Abviva, Inc. is a biomedical company engaged in the innovation,
development and commercialization of breast cancer-related
applications of Mammastatin, a growth inhibitory protein discovered
at the University of Michigan Cancer
Center that demonstrated anti-breast cancer properties. The
discovery was developed into a simple breast cancer diagnostic
blood test that demonstrated healthy women have high or normal
levels of the protein and women with breast cancer have no
detectable or very low levels of the protein. Abviva intends to
commercialize the Mammastatin Serum Assay as a reference test
through its wholly owned subsidiary laboratory under CLIA
certification.
Statements in this press release that are not strictly
historical facts are “forward-looking” statements (iden
‘/>”/>
